Advancing antiviral therapeutics for immunocompromised populations
With few antiviral options available to immunocompromised patients, a new generation of therapies - like AIC468 - is aiming to change that.
List view / Grid view
With few antiviral options available to immunocompromised patients, a new generation of therapies - like AIC468 - is aiming to change that.
28 November 2016 | By Niamh Louise Marriott, Digital Editor
This preclinical study should explore the potential of AIC649 to cure infections caused by hepatitis B virus (HBV) and is investigating the efficacy...
5 January 2016 | By Victoria White
AIC649 is an inactivated parapoxvirus ovis particle preparation with distinct immunological activities including regulated cytokine release and activation of T-cell responses...